View Older Stories View More Recent Stories
-
Research Alliance Corporation III prices $75 million IPO at $10 per share
-
Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Sana Biotechnology raises $69 million through share sale
-
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Artiva Biotherapeutics prices $300 million stock and warrant offering
-
Form SCHEDULE 13G Altimmune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Prelude Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Climb Bio raises $110 million in private placement
-
Form SCHEDULE 13G JATT II Acquisition Corp Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Altimmune closes $225 million public offering for liver drug development
-
Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Prelude Therapeutics prices $90 million stock offering at $4.44 per share
-
Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Tyra Biosciences appoints Habib Dable to board of directors
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Galera and Obsidian merge in $350 million all-stock deal
-
Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
-
Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G OnKure Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Zai Lab Ltd Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cyclerion and Korsana announce $380 million merger deal
-
Form SCHEDULE 13G Xencor Inc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
OnKure raises $150 million to advance cancer treatment programs
-
Karyopharm raises $30 million in private placement with RA Capital
-
Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Equillium, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ovid Therapeutics prices $60 million private placement for drug development
-
Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

